cn3
Monday, 16 April 2018
Bristol-Myers Has Farther to Fall
Bristol-Myers Squibb shareholders have a valuation problem after releasing mixed clinical data in a carefully watched trial for patients with lung cancer.
from WSJ.com: Markets https://ift.tt/2qCXhR6
via https://ifttt.com/ IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment